Results for this period
Full year1 April 2025–31 March 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Net sales increased due to securing customer accounts, sales activities leveraging purchasing data, expanding the range of products handled, and higher selling prices. Operating profit declined because the increase in selling, general and administrative expenses, including higher personnel and logistics costs, exceeded the increase in gross profit.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥1,237,846 million (YoY +4.2%) |
| Operating profit | ¥26,430 million (YoY -5.6%) |
| Ordinary income | ¥29,807 million (YoY -5.9%) |
| Profit attributable to owners of the parent | ¥22,031 million (YoY -3.6%) |
| Operating Margin | 2.14% |
| Equity ratio | End of the current fiscal period 56.7% / End of previous period 56.7% |
| Total assets | ¥532,171 million |
| Net assets | ¥301,738 million |
| Cash flows from operating activities | ¥24,929 million |
| Cash flows from investing activities | ¥-402 million |
| Cash flows from financing activities | ¥-11,160 million |
| Cash and cash equivalents at end of period | ¥83,282 million |
| Annual Dividend Forecast | ¥120 per share → No Dividend |
| Shareholder Return Policy | Targeting a dividend payout ratio of at least 35%, continuing to increase dividends at a pace exceeding profit growth, and conducting flexible share repurchases |
| Depreciation and amortization | ¥6,364 million |
| Impairment loss | ¥104 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Item Gain on sale of investment securities / Amount ¥1,905 million, Item Insurance proceeds received / Amount ¥478 million / Extraordinary loss Item Loss on Disposal of Fixed Assets / Amount ¥20 million, Item Impairment Losses / Amount ¥104 million, Item Impairment Loss on Investment Securities / Amount ¥210 million, Item Impairment Losses on Shares of Affiliates / Amount ¥97 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Material subsequent events | Following a tender offer for the Company's shares by Medipal Holdings Corporation and subsequent procedures, the Company's shares are scheduled to be delisted and the Company is scheduled to become a wholly owned subsidiary. |
| Issued Shares at Period-End | 62,000,000 |
| Treasury Shares at Period-End | 1,205,776 |
| Factors Behind Changes in Business Performance | Net sales increased due to securing customer accounts, sales activities leveraging purchasing data, expanding the range of products handled, and higher selling prices. Operating profit declined because the increase in selling, general and administrative expenses, including higher personnel and logistics costs, exceeded the increase in gross profit. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Net sales increased as a result of securing customer accounts, sales activities leveraging purchasing data, expanding the range of products handled, maintaining sales volumes at the previous year's level, and higher selling prices. Although gross profit increased, operating profit declined because the increase in selling, general and administrative expenses, mainly due to higher personnel and logistics costs, exceeded the increase in gross profit. The reason no earnings forecast or dividend forecast is provided for the next fiscal year is that the Company is scheduled to be delisted following a tender offer by Medipal Holdings Corporation and subsequent procedures.